Production of specific antibodies against SARS-coronavirus nucleocapsid protein without cross reactivity with human coronaviruses 229E and OC43

Lee, Hyun Kyoung; Lee, Byoung Hee; Seok, Seung Hyeok; Baek, Min Won; Lee, Hui Young; Kim, Dong Jae; Na, Yi Rang; Noh, Kyoung Jin; Park, Sunghoon; Dutta, Noton K.; Kariwa, Hiroaki; Nakauchi, Mina; Heo, Suk Jin; Park, Jae Hak

doi:10.4142/jvs.2010.11.2.165

Cited by 95 publications

(80 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…12 It was reported that after SARS infection, IgM antibody could be detected in patient blood after 3 -6 days and IgG could be detected after 8 days. 13,14 Since COVID-19 belongs to the same large family of viruses as those that cause the MERS and SARS outbreak, we assume its antibody generation process is similar, and detection of the IgG and IgM antibody against SARS-CoV-2 will be an indication of infection. Furthermore, detection of IgM antibodies tends to indicate a recent exposure to SARS-CoV-2, whereas detection of COVID-19 IgG antibodies indicates virus exposure some time ago.…”

Section: Accepted Articlementioning

confidence: 99%

Development and clinical application of a rapid IgM‐IgG combined antibody test for SARS‐CoV‐2 infection diagnosis

Luo

et al. 2020

Journal of Medical Virology

1,547

1,710

View full text Add to dashboard Cite

The outbreak of the novel coronavirus disease quickly spread all over China and to more than 20 other countries. Although the virus (SARS-Cov-2) nucleic acid RT-PCR test has become the standard method for diagnosis of SARS-CoV-2 infection, these real-time PCR test kits have many limitations. In addition, high false negative rates were reported. There is an urgent need for an accurate and rapid test method to quickly identify large number of infected patients and asymptomatic carriers to prevent virus transmission and assure timely treatment of patients.We have developed a rapid and simple point-of-care lateral flow immunoassay which can detect IgM and IgG antibodies simultaneously against SARS-CoV-2 virus in human blood within 15 minutes which can detect patients at different infection stages. With this test kit, we carried out clinical studies to validate its clinical efficacy uses. The clinical detection sensitivity and specificity of this test were measured using blood samples collected from 397 PCR confirmed COVID-19 patients and 128 negative patients at 8 different clinical sites. The overall testing sensitivity was 88.66% and specificity was 90.63%. In addition, we evaluated clinical diagnosis results obtained from different types of venous and fingerstick blood samples. The results indicated great detection consistency among samples from fingerstick blood, serum and plasma of venous blood. The IgM-IgG combined assay has better utility and sensitivity compared with a single IgM or IgG test. It can be used for the rapid screening of SARS-CoV-2 carriers, symptomatic or asymptomatic, in hospitals, clinics, and test laboratories.

show abstract

Section: Accepted Articlementioning

confidence: 99%

Development and clinical application of a rapid IgM‐IgG combined antibody test for SARS‐CoV‐2 infection diagnosis

Luo

et al. 2020

Journal of Medical Virology

1,547

1,710

View full text Add to dashboard Cite

show abstract

“…Thus, the process of generating antibodies against SARS‐CoV‐2 might be similar, and the detection of both IgM and IgG antibodies could provide information on the time course of virus infection 10,14 . Following a SARS infection, IgM is detectable after 3–6 days, and IgG is detectable after 8 days 15 . Most recently, serological tests for virus‐specific IgM and IgG antibodies against SARS‐CoV‐2 have been developed, and similar serological responses were observed in one COVID‐19 patient 11,16 .…”

Section: Introductionmentioning

confidence: 99%

Detection of IgM and IgG antibodies in patients with coronavirus disease 2019

et al. 2020

View full text Add to dashboard Cite

Objectives. This study aimed to determine the IgM and IgG responses against severe acute respiratory syndrome coronavirus (SARS-CoV)-2 in coronavirus disease 2019 (COVID-19) patients with varying illness severities. Methods. IgM and IgG antibody levels were assessed via chemiluminescence immunoassay in 338 COVID-19 patients. Results. IgM levels increased during the first week after SARS-CoV-2 infection, peaked 2 weeks and then reduced to near-background levels in most patients. IgG was detectable after 1 week and was maintained at a high level for a long period. The positive rates of IgM and/or IgG antibody detections were not significantly different among the mild, severe and critical disease groups. Severe and critical cases had higher IgM levels than mild cases, whereas the IgG level in critical cases was lower than those in both mild and severe cases. This might be because of the high disease activity and/or a compromised immune response in critical cases. The IgM antibody levels were slightly higher in deceased patients than recovered patients, but IgG levels in these groups did not significantly differ. A longitudinal detection of antibodies revealed that IgM levels decreased rapidly in recovered patients, whereas in deceased cases, either IgM levels remained high or both IgM and IgG were undetectable during the disease course. Conclusion. Quantitative detection of IgM and IgG antibodies against SARS-CoV-2 quantitatively has potential significance for evaluating the severity and prognosis of COVID-19.

show abstract

“…Since early March, serology testing has been involved in updated China national guidelines as a direct evidence for COVID-19 diagnosis. Coupled with manifestation of viral pneumonia on chest CT images, or close-contact [8] and SARS-Cov-2 infection [5], IgM seroconversion took place in acute infection period, while IgG could be detected later on, generally within a week. In addition, the turn-aroundtime for SARS-CoV-2 serology testing were generally only 15 min to 1 h, and the assay could be equipment-free (e.g.…”

mentioning

confidence: 99%

Significance of serology testing to assist timely diagnosis of SARS-CoV-2 infections: implication from a family cluster

Xiao

Liu

et al. 2020

Emerging Microbes & Infections

View full text Add to dashboard Cite

2020) Significance of serology testing to assist timely diagnosis of SARS-CoV-2 infections: implication from a family cluster, Emerging Microbes & Infections, 9:1, 924-927, ABSTRACTConfirmative diagnosis of SARS-CoV-2 infections has been challenged due to unsatisfactory positive rate of molecular assays. Here we identified a family cluster of SARS-CoV-2 infections, with five of six family members were SARS-CoV-2specific immunoglobin serology testing positive, while molecular assays only detected two of this five patients even repeated twice. We comprehensively analyzed this familial cluster of cases based on the clinical characteristics, chest CT images, SARS-CoV-2 molecular detection results, and serology testing results. At last, two patients were diagnosed with COVID-19, two were suspected of COVID-19, and two were considered close contacts. Our results emphasized the significance of serology testing to assist timely diagnosis of SARS-CoV-2 infections, especially for COVID-19 close contacts screening.

show abstract

Production of specific antibodies against SARS-coronavirus nucleocapsid protein without cross reactivity with human coronaviruses 229E and OC43

Cited by 95 publications

References 12 publications

Development and clinical application of a rapid IgM‐IgG combined antibody test for SARS‐CoV‐2 infection diagnosis

Development and clinical application of a rapid IgM‐IgG combined antibody test for SARS‐CoV‐2 infection diagnosis

Detection of IgM and IgG antibodies in patients with coronavirus disease 2019

Significance of serology testing to assist timely diagnosis of SARS-CoV-2 infections: implication from a family cluster

Contact Info

Product

Resources

About